Nevrox Overview
- Year Founded
-
2019
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Nevrox General Information
Description
Developer of neuroprotective small molecule drug intended for the treatment of Huntington's disease (HD) and Amyotrophic Lateral Sclerosis (ALS). The company targets neurodegenerative disorders, enabling healthcare professionals to avoid characteristic misfolded proteins that aggregate and induce neuronal toxicity and death.
Contact Information
Corporate Office
- Rehov Ilan Ramon 2
- Ness Ziona 7403635
- Israel
Corporate Office
- Rehov Ilan Ramon 2
- Ness Ziona 7403635
- Israel
Nevrox Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Out of Business | 01-Sep-2022 | Completed | Out of Business | |||
| 2. Seed Round | 01-Nov-2019 | Completed | Startup | |||
| 1. Accelerator/Incubator | Completed | Startup |
Nevrox Patents
Nevrox Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022264142-A1 | Benzothiazole based compounds and use thereof as protein disulphide isomerase inhibitors | Inactive | 15-Jun-2021 |
Nevrox FAQs
-
When was Nevrox founded?
Nevrox was founded in 2019.
-
Where is Nevrox headquartered?
Nevrox is headquartered in Ness Ziona, Israel.
-
What industry is Nevrox in?
Nevrox’s primary industry is Drug Discovery.
-
Is Nevrox a private or public company?
Nevrox is a Private company.
-
What is Nevrox’s current revenue?
The current revenue for Nevrox is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
